Skip to main content
Premium Trial:

Request an Annual Quote

KineMed, Pfizer Renew Research Collaboration

NEW YORK (GenomeWeb News) – KineMed today announced the renewal of its non-exclusive research collaboration with Pfizer.

The deal was originally forged a year ago and seeks to develop new approaches to specific metabolic diseases, in particular type 2 diabetes. Under the agreement, KineMed's dynamic proteomics technology platform will be used to map the impact of potential drug candidates, the Emeryville, Calif.-based company said.

KineMed's technology uses wide-scale isotopic labeling and mass spectrometry to track protein activity kinetics, which can elucidate biological pathways and disease processes.

Citing statistics from the World Health Organization, KineMed said that diabetes affects about 347 million people worldwide. In the US, about 25 percent of the 65-and-over population is affected by type 2 diabetes. Despite extensive research into the disease, more than 60 percent of patients do not respond to current therapies, necessitating new approaches "to address fundamental metabolic processes," KineMed said.

Financial and other terms of the deal were not disclosed.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.